{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T13:11:02Z","timestamp":1777295462612,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014935","name":"BioCryst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014935","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["worldallergyorganizationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Allergy Organization Journal"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.waojou.2024.100882","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T12:58:43Z","timestamp":1709384323000},"page":"100882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-7562","authenticated-orcid":false,"given":"Daisuke","family":"Honda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1569-6034","authenticated-orcid":false,"given":"Michihiro","family":"Hide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2773-9791","authenticated-orcid":false,"given":"Tomoo","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4586-5936","authenticated-orcid":false,"given":"Keisuke","family":"Koga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5427-8468","authenticated-orcid":false,"given":"Eishin","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0803-9455","authenticated-orcid":false,"given":"Shinichi","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7752-7180","authenticated-orcid":false,"given":"Yoshihiro","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4077-9747","authenticated-orcid":false,"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phil","family":"Collis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas T.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianne","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavisha","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1267-5585","authenticated-orcid":false,"given":"Isao","family":"Ohsawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.waojou.2024.100882_bib1","first-page":"48","article-title":"Hereditary angioedema: a review","volume":"121","author":"Zafra","year":"2022","journal-title":"Wis Med J"},{"issue":"Suppl 1","key":"10.1016\/j.waojou.2024.100882_bib2","doi-asserted-by":"crossref","first-page":"S03","DOI":"10.2500\/aap.2020.41.200040","article-title":"Definition and classification of hereditary angioedema","volume":"41","author":"Proper","year":"2020","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"10.1016\/j.waojou.2024.100882_bib3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.waojou.2024.100882_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2169\/internalmedicine.8624-16","article-title":"Clinical features of hereditary and mast cell-mediated angioedema focusing on the differential diagnosis in Japanese patients","volume":"57","author":"Ohsawa","year":"2018","journal-title":"Intern Med"},{"issue":"5","key":"10.1016\/j.waojou.2024.100882_bib5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2500\/aap.2010.31.3394","article-title":"The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression","volume":"31","author":"Lumry","year":"2010","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"10.1016\/j.waojou.2024.100882_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2500\/aap.2013.34.3685","article-title":"The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe","volume":"35","author":"Caballero","year":"2014","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"10.1016\/j.waojou.2024.100882_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5582\/irdr.2022.01130","article-title":"Burden of illness seen in hereditary angioedema in Japanese patients: results from a patient reported outcome survey","volume":"12","author":"Yamamoto","year":"2023","journal-title":"Intractable Rare Dis Res"},{"issue":"3","key":"10.1016\/j.waojou.2024.100882_bib8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.amjmed.2005.09.064","article-title":"Hereditary angioedema: new findings concerning symptoms, affected organs, and course","volume":"119","author":"Bork","year":"2006","journal-title":"Am J Med"},{"issue":"Suppl 1","key":"10.1016\/j.waojou.2024.100882_bib9","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.2500\/aap.2020.41.200065","article-title":"Clinical presentation of hereditary angioedema","volume":"41","author":"Azmy","year":"2020","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"10.1016\/j.waojou.2024.100882_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2023.100792","article-title":"The multifactorial impact of receiving a hereditary angioedema diagnosis","volume":"16","author":"Raasch","year":"2023","journal-title":"World Allergy Organ J"},{"issue":"1","key":"10.1016\/j.waojou.2024.100882_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1710-1492-9-29","article-title":"Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe","volume":"9","author":"Zanichelli","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"7","key":"10.1016\/j.waojou.2024.100882_bib12","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.waojou.2024.100882_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100627","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema - the 2021 revision and update","volume":"15","author":"Maurer","year":"2022","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.waojou.2024.100882_bib14","unstructured":"HAE International. TAKHZYRO\u00ae approved in Japan. https:\/\/haei.org\/takhzyro-approved-in-japan\/. Accessed 19 September 2023."},{"key":"10.1016\/j.waojou.2024.100882_bib15","unstructured":"HAE International. Approval of Orladeyo in Japan for prophylactic HAE treatment. https:\/\/haei.org\/approval-of-orladeyo-in-japan-for-prophylactic-hae-treatment\/. Accessed 19 September 2023.."},{"key":"10.1016\/j.waojou.2024.100882_bib16","unstructured":"HAE International. Berinert\u00ae S.C. Injection 2000 authorized in Japan. https:\/\/haei.org\/berinert-s-c-injection-2000-authorized-in-japan\/. Accessed 19 September 2023.."},{"issue":"2","key":"10.1016\/j.waojou.2024.100882_bib17","first-page":"103","article-title":"Hereditary angioedema (HAE) guidelines \u2013 revised 2023 edition","volume":"60","author":"Horiuchi","year":"2023","journal-title":"Journal of The Japanese Association for Complement Research"},{"issue":"1","key":"10.1016\/j.waojou.2024.100882_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13223-021-00537-2","article-title":"Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report","volume":"17","author":"Bork","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"10.1016\/j.waojou.2024.100882_bib19","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2500\/aap.2021.42.210025","article-title":"Patient perspectives on the treatment burden of injectable medication for hereditary angioedema","volume":"42","author":"Radojicic","year":"2021","journal-title":"Allergy Asthma Proc"},{"issue":"3","key":"10.1016\/j.waojou.2024.100882_bib20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40265-021-01475-4","article-title":"Berotralstat: first approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.waojou.2024.100882_bib21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jaci.2020.10.015","article-title":"Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"148","author":"Zuraw","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.waojou.2024.100882_bib22","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1111\/all.14670","article-title":"Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial","volume":"76","author":"Ohsawa","year":"2021","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.waojou.2024.100882_bib23","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/all.12007","article-title":"Development and construct validation of the angioedema quality of life questionnaire","volume":"67","author":"Weller","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.waojou.2024.100882_bib24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcome"},{"issue":"1","key":"10.1016\/j.waojou.2024.100882_bib25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12955-019-1229-3","article-title":"Angioedema quality of life questionnaire (AE-QoL) - interpretability and sensitivity to change","volume":"17","author":"Kulthanan","year":"2019","journal-title":"Health Qual Life Outcome"},{"issue":"8","key":"10.1016\/j.waojou.2024.100882_bib26","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/all.12900","article-title":"The Angioedema Quality of Life Questionnaire (AE-QoL) - assessment of sensitivity to change and minimal clinically important difference","volume":"71","author":"Weller","year":"2016","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.waojou.2024.100882_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12035","article-title":"Long-term safety and effectiveness of berotralstat for hereditary angioedema: the open-label APeX-S study","volume":"11","author":"Farkas","year":"2021","journal-title":"Clin Transl Allergy"},{"issue":"6","key":"10.1016\/j.waojou.2024.100882_bib28","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.jaip.2021.03.057","article-title":"Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2)","volume":"9","author":"Wedner","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2024.100882_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2023.12.019","article-title":"Once-daily oral berotralstat for long-term prophylaxis of hereditary angioedema: the open-label extension of the APeX-2 randomized trial","author":"Kiani-Alikhan","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.waojou.2024.100882_bib30","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.anai.2010.01.024","article-title":"Economic costs associated with acute attacks and long-term management of hereditary angioedema","volume":"104","author":"Wilson","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.waojou.2024.100882_bib31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2500\/aap.2014.35.3738","article-title":"Quantifying the burden of disease and perceived health state in patients with hereditary angioedema in Sweden","volume":"35","author":"Nordenfelt","year":"2014","journal-title":"Allergy Asthma Proc"},{"issue":"Suppl 1","key":"10.1016\/j.waojou.2024.100882_bib32","doi-asserted-by":"crossref","first-page":"S08","DOI":"10.2500\/aap.2020.41.200050","article-title":"Hereditary angioedema: epidemiology and burden of disease","volume":"41","author":"Lumry","year":"2020","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"10.1016\/j.waojou.2024.100882_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/21556660.2020.1863699","article-title":"Hereditary angioedema patients would prefer newer-generation oral prophylaxis","volume":"10","author":"Geba","year":"2021","journal-title":"J\u00a0Drug Assess"},{"key":"10.1016\/j.waojou.2024.100882_bib34","unstructured":"BioCryst. BioCryst announces approval of Japanese NHI price listing of ORLADEYO\u2122 (berotralstat) for prophylactic treatment of hereditary angioedema. https:\/\/www.globenewswire.com\/fr\/news-release\/2021\/04\/14\/2209965\/29446\/en\/BioCryst-Announces-Approval-of-Japanese-NHI-Price-Listing-of-ORLADEYO-berotralstat-for-Prophylactic-Treatment-of-Hereditary-Angioedema.html. Accessed 19 September 2023.."},{"key":"10.1016\/j.waojou.2024.100882_bib35","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9157895","article-title":"Angioedema activity score (AAS): a valid and reliable tool to use in Asian patients","volume":"2019","author":"Kulthanan","year":"2019","journal-title":"BioMed Res Int"},{"issue":"5","key":"10.1016\/j.waojou.2024.100882_bib36","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/all.14144","article-title":"Development of the Angioedema Control Test-A patient-reported outcome measure that assesses disease control in patients with recurrent angioedema","volume":"75","author":"Weller","year":"2020","journal-title":"Allergy"}],"container-title":["World Allergy Organization Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455124000139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455124000139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:46:47Z","timestamp":1761850007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1939455124000139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1939455124000139"],"URL":"https:\/\/doi.org\/10.1016\/j.waojou.2024.100882","relation":{},"ISSN":["1939-4551"],"issn-type":[{"value":"1939-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial","name":"articletitle","label":"Article Title"},{"value":"World Allergy Organization Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.waojou.2024.100882","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of World Allergy Organization.","name":"copyright","label":"Copyright"}],"article-number":"100882"}}